Search

everythinglearnresearchcommunity

for

Search:↓

User experienced significant body hair loss from Finasteride and started oral Minoxidil to address crown thinning. Their current regimen includes 1mg Finasteride, 2.5mg Minoxidil, Biotin, Vitamin D, Zinc, Iron, and ketoconazole shampoo.

The user switched from topical to oral finasteride and minoxidil, noticing thicker and longer baby hairs, suggesting potential regrowth at the temples. Other users agree it looks like a sign of success.

The conversation discusses the positive effects of taking 5 mg oral minoxidil and 0.5 mg oral dutasteride every other day for hair loss, with one user reporting thicker beard and eyebrows and improved appearance. Another user expresses frustration about not being able to access the treatment in Germany, while a different user mentions experiencing no side effects.

Controlling insulin levels through intermittent fasting and a low glycemic diet may improve hair quality by reducing androgens. It's important to maintain proper nutrition, including electrolytes and protein, during fasting.

The user experienced tiny vellus hairs from 0.5mg finasteride and 2.5mg minoxidil over 9 months. Topical minoxidil, alfatradiol, and RU58841 applied twice daily for 1.5 months significantly improved temple hair regrowth.

The user has been treating hair loss for over 11 years with various methods including Minoxidil, Keto shampoos, vitamins, and microneedling, but has avoided Finasteride due to fertility concerns. They have recently added Zix and The Ordinary Serum to their routine and are questioning their high DHT levels despite their efforts.

The user shared progress after four months of using a topical treatment with 0.3% finasteride and 6% minoxidil from Hims, noting positive results and considering switching to oral medication for convenience. Other users discussed the effectiveness of minoxidil and finasteride, emphasizing that first-time users often see the best results, and shared personal experiences with hair regrowth and maintenance.

The user experienced severe side effects from oral finasteride, including sexual dysfunction and mental health issues, and switched to topical finasteride, which led to significant hair shedding. They are considering other treatments like RU58841 or topical dutasteride and are advised to check testosterone levels and address potential underlying health issues.

The conversation discusses hair loss treatment progress using 1mg oral finasteride, 10% minoxidil, biotin 0.2%, and LATANO 0.005%. One user reports improved confidence, while another mentions increased libido and a history of depression.

The user reported hair thickening after two months of using topical 7% minoxidil and 0.1% dutasteride, with no side effects. They previously experienced side effects with oral finasteride and switched to the topical treatment.

The user started using finasteride, minoxidil, and biotin for hair loss and believes they are a hyper responder, noticing significant changes in hair thickness. They regret not starting earlier and mention using oral minoxidil.

A trans woman is experiencing hair loss and is considering treatments like cyproterone, dutasteride, and oral minoxidil. She is concerned about potential hair growth on her face, chest, or legs due to minoxidil.

Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.

The conversation discusses treating male pattern baldness in a transgender woman using cyproterone acetate, finasteride, and biotin. The original poster shared their experience for others who might be in a similar situation.

The conversation discusses a user experiencing short, curly, wiry hair above and behind the ears, linking it to pattern baldness. The user suggests starting treatment early but personally chose not to pursue treatments like Minoxidil, finasteride, or RU58841 due to the hassle.

Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The user discusses a galenic hair lotion containing progesterone, estradiol, cyproterone, hydrocortisone butyrate, and cetirizine pheniramine, which has effectively stopped their hair loss over two years. They are curious about the compatibility of finasteride with the lotion's components and note that their trichologist has successfully used minoxidil and finasteride in similar treatments for others.

User is experiencing hair thinning and sebum overproduction after starting finasteride and a hair growth supplement containing biotin, iron, zinc, and calcium. They suspect the finasteride might be fake but have noticed a side effect of watery semen.

The user observed new tiny white hairs after 12 days of using minoxidil, finasteride, microneedling, and biotin, hoping they will become terminal hairs. Others advise that while some hairs may not fully grow, consistent treatment, patience, and scalp massages could enhance results.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

A 27-year-old man shared his hormonal panel results after one year of taking finasteride 1mg/day for hair loss, showing his DHT levels nearly doubled. He reported stabilized hair loss with mild side effects that resolved, and he is considering a hair transplant but is concerned about the increased DHT levels and potential treatment options.

A 23-year-old is experiencing hair that is thick at the ends but thin at the roots despite using minoxidil and finasteride for 10 months. They are concerned about whether this is normal or a sign of miniaturization and seek advice on reversing or improving the condition.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

The user experienced red pimples and a rash from using topical minoxidil, possibly due to propylene glycol. Suggestions included seeing a dermatologist, switching to foam without propylene glycol, using Nizoral, and adjusting application timing.

The conversation discusses starting low-dose oral finasteride for hair loss, considering hormone levels and potential side effects like gynecomastia. Suggestions include using DIM for estradiol, vitamin B6 for prolactin, and lifestyle changes to optimize hormone profiles before starting treatment.

The user has been using finasteride, dutasteride, and RU58841 for hair loss without success and feels extremely uncomfortable with their appearance, including being bald and short. They express deep unhappiness and social isolation. Suggestions from others include adopting stoicism, focusing on personal development, considering a hair system, improving fashion, working out, and seeking therapy for mental health.

Finasteride may inhibit melanin production, affecting tanning and causing white hairs in the beard and eyebrows. The user considers switching to oral Dutasteride or topical treatments to address these issues.

A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.